Search results
2 Top Growth Stocks to Buy Right Now and Hold Forever
Motley Fool via Yahoo Finance· 10 hours agoJohnson & Johnson definitely meets these benchmarks. It looks like a good time to grow or start a...
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
Motley Fool via Yahoo Finance· 4 hours agoOne concern, however...support that high rate of cash burn. The company announced a stock offering...
Is Viking Therapeutics Incredibly Undervalued?
Motley Fool via Yahoo Finance· 9 hours agoVK2735's true value lies thus in the hands of a well-funded big pharma player with the marketing might to compete effectively. This fact...bottom line?...
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Motley Fool via Yahoo Finance· 11 hours agoAs such, this biotech stock is a highly aggressive growth play best suited for individuals with a long-term horizon and a high tolerance for volatility.
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy ...
Motley Fool via Yahoo Finance· 7 days agoThe biotech is also evaluating other promising non-opioid pain therapies in phase 1 and 2 clinical...
3 Millionaire-Maker Biotech Stocks
Motley Fool via Yahoo Finance· 3 days agoThe...if you invested $1,000 at the time of our recommendation, you’d have $505,010!* Stock Advisor provides investors with an easy-to-follow blueprint...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 3 days agoNeurocrine is well known for its approved drug, Ingrezza, which treats tardive...affect a child's...
Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.
Motley Fool via Yahoo Finance· 2 days agoI'm most excited, though, about the rest of Vertex's pipeline. The biotech expects to soon file for...
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Motley Fool via Yahoo Finance· 6 days agoIf we add to this the pain treatment opportunity and the potential of povetacicept as well as...
Can This High-Flying Stock 10x in 10 Years?
Motley Fool via Yahoo Finance· 10 hours agoBut how likely is that to happen? It's hard to say. Biotech companies, especially smaller ones, often encounter unexpected regulatory obstacles...
